Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.34 |
| ▸ | MAOB | P27338 | 4/20 | 0.34 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TYMS | P04818 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201287 | 0.71 | CHEK1 (0.36) | MAOAMAOBGAAMAPTCYP1A2 | |
| SCHEMBL2200286 | 0.70 | KCNJ1 (0.44) | MAOAMAOBKCNJ1ALOX5LMNA | |
| SCHEMBL855938 | 0.69 | ALOX5 (0.39) | MAOAMAOBKCNJ1ALOX5LMNA | |
| SCHEMBL854575 | 0.69 | KCNJ1 (0.46) | MAOAMAOBKCNJ1ALOX5LMNA | |
| SCHEMBL12444323 | 0.68 | KDM4E (0.45) | KCNJ1KDM4ECYP1A2CYP2C19 | |
| SCHEMBL7412699 | 0.68 | ALOX5 (0.42) | MAOAMAOBKCNJ1ALOX5MAPT | |
| SCHEMBL31084562 | 0.67 | MAPT (0.44) | MAOAMAOBKCNJ1LMNAGAA | |
| SCHEMBL903470 | 0.67 | MAPT (0.44) | MAOAMAOBKCNJ1LMNAGAA | |
| SCHEMBL861759 | 0.67 | MAOA (0.38) | MAOAMAOBKCNJ1ALOX5LMNA | |
| SCHEMBL855133 | 0.67 | KCNJ1 (0.44) | MAOAMAOBKCNJ1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455535-B2 | Heteroaryl dihydroindolones as kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110257238-A1 | Heteroaryl Dihydroindolones as Kinase Inhibitors | ALLERGAN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7977351-B2 | Heteroaryl dihydroindolones as kinase inhibitors | ALLERGAN, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257238-A1 | Heteroaryl Dihydroindolones as Kinase Inhibitors | REN, JAK2, ABL1 | MAOA 1387/4885MAOB 958/4885KCNJ1 2909/4885 |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | REN, JAK2, ABL1 | MAOA 1387/4885MAOB 958/4885KCNJ1 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.